• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Is there an inapparent dengue explosion?

sharon sanders

Editor-in-Chief & President
The Lancet 1999; 353:1101
DOI:10.1016/S0140-6736(05)76461-8
Is there an inapparent dengue explosion?
Jos? G Rigau-P?rez a and Duane J Gubler a

See Correspondence

Authors' reply
Sir?We agree with Scott Halstead that many dengue infections are clinically inapparent, and their frequency varies with the strain of virus and the epidemiological circumstances. Dengue infection causes a spectrum of illness ranging from truly inapparent infection, through mild viral syndrome and classic dengue fever, to DHF. As a result of poor surveillance, many clinically mild dengue infections are not reported as dengue fever but as malaria or viral syndrome.
Annual global reports of dengue cases to WHO averaged over 340 000 for 1991?95.1 Most locations, even with good reporting, will have a ratio of diagnosed to reported dengue fever cases of at least 10/1, and in many areas (owing to mild cases, misdiagnosis, and difficulties of reporting), the ratio of dengue fever cases with symptoms to those actually reported may be higher than 100/1. In view of the poor surveillance for dengue fever in most countries, the high frequency, and expansion of epidemic dengue in past years, we believe that the estimate of 50?100 million aanual cases of dengue fever is valid.
Case fatality rates are the ratio of fatal cases to the number of patients with the illness (usually expressed as a percentage). Halstead cites case fatality rates that refer to groups of patients that differ from the group we examined. The rates he cites for Asian nations (0?05?3?5%) represent the number of deaths per 100 cases of DHF or dengue shock syndrome (DSS). The case fatality rate for Cuba in 1981 (1?5%) represents the number of deaths per 100 dengue cases admitted to hospital. These values are lower than the case fatality rate for DSS, because the denominators include patients with less severe illness than DSS. The placebocontrolled, double-blind trial of steroid treatment for severe DSS by Tassniyom and colleagues2 done in an academic setting in which there was management experience of DSS showed a case fatality rate of 12?7%. Among four other studies presented in that report, we referred only to the highest reported case-fatality rate, but our phrasing indicates that this is an extreme value (?can be as high as??), and not the benchmark. The few reports available on the case fatality rate of DSS have small sample sizes, and may produce inaccurate estimates. We therefore hope that this discussion will encourage other researchers to report case-fatality rates in dengue patients with well characterised severity stages (such as hypotension or shock). Carerful attention to blood pressure in all patients should result in improved care, because the prognosis for DHF and DSS depends on prevention or early recognition and treatment of shock.


<!--start simple-tail=-->References

1. WHO. Dengue haemorrhagic fever; diagnosis, treatment, prevention and control. Geneva: WHO, 1997:.
2. Tassniyom S, Vasanawathana S, Chirawatkul A, Rojanasuphot F. Failure of high dose methylprednisone in established dengue shock synndrome: a placebocontrolled, double-blind study. Pediatrics 1993; 92: 111-115. MEDLINE
Back to top
 
Re: Is there an inapparent dengue explosion?

The Lancet 1999; 353:1100-1101
DOI:10.1016/S0140-6736(05)76460-6
Is there an inapparent dengue explosion?Scott B Halstead a

Sir
Jos? Rigau-Perez and colleagues,1 inflation of global annual morbidity data and case fatality rates for dengue could have serious unintended consequences. In their introductory paragraphs, the investigators estimate 50?100 million dengue cases annually. A number of this magnitude was first suggested in 1988.2 It is becoming increasingly clear, however, that most dengue infections are inapparent. Although dengue fever is reported in only a few countries, comprehensive data for dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) have been reported to regional offices of WHO for more than 30 years. Summaries have been published from time to time.3 For many western and other countries, these data include cases of dengue fever, but global totals seldom exceed 500 000 annually. Most of the estimated 50?100 million dengue infections occur in children, and when studied carefully, are largely silent.
In their summary, the investigators state that ?case fatality rates in patients with dengue shock syndrome can be as high as 44%.? This value is taken from a fairly small hospital-based treatment study (the case fatality rate reported in the original text was 38%) in which the most severely ill patients were recruited to allow an evaluation of a putative life saving therapeutic regimen.4 Nowhere are reliable national statistics available for incidence of DSS. As a result, DSS case fatality rates are not well known. Case fatality rates for DHF and DSS are available.3 For 12 Asian countries, cumulative DHF-DSS case fatality rates vary between 0?5% and 3?5%.
Physicians need reliable data on prognosis of DHF and DSS to plan treatment regimens, allocate scarce resources and counsel families. In the Americas, Cuban physicians, confronted for the first time with DHF and DSS, took justifiable pride in achieving a case fatality rate of 1?5% among 10 000 cases admitted in the 1981 epidemic.5 This rate is the benchmark, and not 44%.


<!--start simple-tail=-->References

1. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet 1998; 352: 971-977. Abstract | Full Text | PDF (193 KB) | CrossRef
2. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239: 476-481. MEDLINE
3. Halstead SB. Epidemiology of dengue and dengue hemorrhagic fever In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. Wallingford, UK: CAB International, 1997: 23-44.
4. Min M, Tin U, Aye M, Shwe TN, Swe T, Aye B. Hydrocortisone in the management of dengue shock syndrome. Southeast Asian J Trop Med Public Health 1975; 6: 573-579.
5. Kouri G, Guzman MG, Bravo JR, Triana C. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull Work Health Organ 1989; 67: 375-380.
Back to top
 
Re: Is there an inapparent dengue explosion?

Experts fear dengue-II which caused 550 deaths in '96
http://in.news.yahoo.com/061003/48/685wd.html



Wednesday October 4, 01:03 AM
WITH the number of dengue cases in the Capital on the rise, experts are trying to find the strain of virus responsible for this year's outbreak. While there are four distinct, but closely related viruses, that cause dengue, experts suspect that the Capital could be in grip of dengue-II (dengue haemorrhagic fever with shock), a severe form of the infection.

The experts are basing their suspicion on the trends which the virus has been following in the city in past years. Cases of dengue-II were last seen in 2002 and 2004. In 2003 and 2005, however, dengue-III (dengue haemorrhagic fever without shock) cases was reported.

"We have seen a particular serotype getting submerged for one year and then coming back again. The break for a year for that particular serotype helps it evolve and infect again. Keeping in view these trends, there is a possibility that this could be dengue-II," said a source in the National Institute of Communicable Diseases (NICD).

The NICD as well as the All India Institute of Medical Sciences (AIIMS) are working to find out the serotype.

"It will take another three-four days to isolate the virus. Our experts are working on isolating the virus. If there is a change in strain, then there is a hyper-immune response in those who had the infection in the past," said Dr Randeep Guleria, professor of medicine in AIIMS.

The possibility of dengue-II is a cause of concern. In 1996, the virus led to around 550 deaths, with over 10,500 people infected with the fever in the city.

"Dengue-II is one of those strains which is known to be responsible for large number of complications. Its combination with another serotype like dengue-IV is dangerous. It's definitely a cause of concern if it's serotype II, and the civic bodies should be extra conscious," said a senior doctor in Bara Hindu Rao.

Dengue strains
* Dengue I: Classical dengue fever; high fever, pain in joints
* Dengue II: Dengue haemorrhagic fever with shock; spontaneous bleeding of skin and gums
* Dengue III: Dengue haemorrhagic fever without shock; circulatory failure, agitation
* Dengue IV: Dengue haemorrhagic fever without shock; profound shock (unrecordable blood pressure)
_________________
 
Back
Top